Effects of Daratumumab(dara), Cyclophosphamide (C), Thalidomide (T) and Dexamethasone (D) Combination on Lymphocyte Populations of Transplant Eligible Newly Diagnose Multiple Myeloma Patients

被引：0

作者：

Santos, Allan ^{[1
]}

Santos, Herbert ^{[2
]}

Leal, Joanna ^{[3
]}

Santos, Juliana ^{[2
,3
]}

Salvino, Marco ^{[4
]}

Lucas, Larissa ^{[3
]}

Santos, Mariane ^{[1
]}

Hungria, Vania T. M. ^{[5
]}

Torres, Alex ^{[6
]}

Crusoe, Edvan de Queiroz ^{[7
]}

机构：

[1] Univ Fed Bahia, Immunol & Cytometry Lab, Salvador, BA, Brazil

[2] Univ Fed Bahia, Salvador, BA, Brazil

[3] Oncol DOr BA Brazil, Salvador, BA, Brazil

[4] Univ Fed Bahia, Bone Marrow Transplantat unit, Salvador, BA, Brazil

[5] Clin Sao Germano Sao Paulo, Dept Hematol, Sao Paulo, Brazil

[6] Univ Fed Bahia, Inst Ciencias Saude, Salvador, BA, Brazil

[7] Rede Dor Oncol, Salvador, BA, Brazil

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-244

引用

页码：S178 / S179

页数：2

共 50 条

[21] Correction to: Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
Yvette N. Lamb
Drugs, 2021, 81 : 183 - 183
[22] Real-World Data on the Daratumumab Plus Bortezomib, Thalidomide and Dexamethasone Followed by Lenalidomide Maintenance for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
Crusoe, Edvan de Queiroz
Ribeiro, Glaciano
Moura, Fernanda
Costa, Abel
Aranha, Milton
Bittencourt, Rosane
Ribeiro, Eduardo
Neto, Jorge
Cunha, Rafael
Mattos, Ederson
Braga, Walter
Lima, Juliana Souza
Gusmao, Breno
Lopes, Danielle Ovigli
Berg, Luiza
Souto, Joao
Maiolino, Angelo
Hungria, Vania T. M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S223 - S223
[23] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah A.
Anderson, Larry D., Jr.
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Bartlett, J. Blake
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter
BLOOD CANCER JOURNAL, 2022, 12 (04)
[24] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2020, 136 (08) : 936 - 945
[25] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Ajay K. Nooka
Jonathan L. Kaufman
Cesar Rodriguez
Andrzej Jakubowiak
Yvonne Efebera
Brandi Reeves
Tanya Wildes
Sarah A. Holstein
Larry D. Anderson
Ashraf Badros
Leyla Shune
Ajai Chari
Huiling Pei
Annelore Cortoos
Sharmila Patel
J. Blake Bartlett
Jessica Vermeulen
Thomas S. Lin
Paul G. Richardson
Peter Voorhees
Blood Cancer Journal, 12
[26] Induction Therapy with Bortezomib-Cyclophosphamide-Dexamethasone (BCD) for Newly Diagnosed Transplant Eligible Patients with Multiple Myeloma
Tsukada, Nobuhiro
Ikeda, Masahiro
Shingaki, Sumito
Miyazaki, Kanji
Meshitsuka, Sosuke
Abe, Yu
Yoshiki, Yumiko
Suzuki, Kenshi
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S205 - S205
[27] Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma
Sidra, Gamal
Williams, Cathy D.
Russell, Nigel H.
Zaman, Sonya
Myers, Bethan
Byrne, Jennifer L.
HAEMATOLOGICA, 2006, 91 (06) : 862 - 863
[28] Bortezomib, Thalidomide and Dexamethasone Compared to Cyclophosphamide, Bortezomib and Dexamethasone As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma: Real World Experience with Multiple Myeloma Patients in Colombia
Cesar Solano, Julio
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S248 - S248
[29] Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2
Loiseau, Herve Avet
Sonneveld, Pieter
Moreau, Philippe
Offner, Fritz
van der Velden, Vincent H. J.
Caillot, Denis
Hulin, Cyrille
Arnulf, Bertrand
Corre, Jill
Mohty, Mohamad
Karlin, Lionel
Lambert, Jerome
Macro, Margaret
Perrot, Aurore
Levin, Mark-David
Klein, Saskia K.
Stoppa, Anne-Marie
Delforge, Michel
Zweegman, Sonja
Jie, Kon-Siong
Van De Donk, Niels W. C. J.
Krevvata, Maria
Rigat, Fabio
Yang, Shiyi
Vanquickelberghe, Veronique
de Boer, Carla
Kampfenkel, Tobias
Vermeulen, Jessica
Wuilleme, Soraya
Broyl, Annemiek
Bene, Marie C.
BLOOD, 2021, 138
[30] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTD) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-Risk Patients in Cassiopeia
Sonneveld, Pieter
Attal, Michel
Perrot, Aurore
Hulin, Cyrille
Caillot, Denis
Facon, Thierry
Leleu, Xavier
Belhadj, Karim
Karlin, Lionel
Benboubker, Lotfi
Levin, Mark-David
Minnema, Monique C.
Westerman, Matthijs
Delforge, Michel
Zweegman, Sonja
Pei, Lixia
de Boer, Carla
Vanquickelberghe, Veronique
Kampfenkel, Tobias
Moreau, Philippe
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 124 - 126

← 1 2 3 4 5 →